These inhibitory activities of NGFR toward p53 are ligand-independent, as they occurred in the nucleus and NGF treatment did not appear to affect p53 level and activity in H460, HCT116, and HepG2 cancer cells tested (Data not shown). The gene discussed is NGFR; the disease is cancer.